


AEP-IN-3

Cat. No.:	HY-162076		
CAS No.:	2978521-26-3		
Molecular Formula:	C ₂₁ H ₂₁ F ₄ N ₃ O ₄		
Molecular Weight:	455.4		
Target:	Others		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (219.59 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.1959 mL	10.9794 mL	21.9587 mL
	5 mM	0.4392 mL	2.1959 mL	4.3917 mL
	10 mM	0.2196 mL	1.0979 mL	2.1959 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: 2.5 mg/mL (5.49 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (5.49 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: 2.5 mg/mL (5.49 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

AEP-IN-3 (compound 18) is an orally active, potent and brain penetrant asparagine endopeptidase (AEP) inhibitor, with an IC₅₀ of 7.8 ± 0.9 nM. AEP-IN-3 can be used for Alzheimer's Disease (AD) research^[1].

In Vivo

AEP-IN-3 (compound 18) has a bioavailability of 83% and a T_{1/2}[1].
AEP-IN-3 (20 mg/kg, orally, BID, for 5 days) shows significantly inhibited activity of AEP in brain in TauP301L transgenic mice [1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice producing the 2N4R isoform of human Tau containing the P301L mutation in aFVB/N genetic background (3.8 months old) ^[1]
Dosage:	20 mg/kg
Administration:	Orally, BID with an interval of 7-8 h between doses for 5 days
Result:	Showed significantly inhibited activity of AEP in brain, reduced formation of the Tau N368 fragment. The effect on total Tau is not significant.

REFERENCES

[1]. Krummenacher D, et al. Discovery of Orally Available and Brain Penetrant AEP Inhibitors. J Med Chem. 2023 Dec 28;66(24):17026-17043.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA